DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to ...

Perrigo Company plc (PRGO) is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results und ...

Perrigo公司出售HRA Pharma Rare Diseases业务 - Perrigo公司宣布将出售HRA Pharma Rare Diseases业务给Esteve Healthcare，总交易金额高达275百万欧元，其中包括1.9亿欧元的现金支付和最多8500万欧元的潜在奖励[1] - 出售HRA Pharma Rare Diseases业务将有助于Perrigo公司降低净杠杆率至2024年底低于4.0倍[2] ESTEVE公司收购HRA Rare Diseases业务 - ESTEVE公司将受益于收购HRA Rare Diseases业务，这一交易旨在满足未满足的患者需求，符合ESTEVE公司改善人们生活的宗旨[2] 财务顾问和法律顾问 - Morgan Stanley & Co. LLC担任Perrigo的财务顾问，Wachtell, Lipton, Rosen & Katz担任其法律顾问；Perella Weinberg Partners担任ESTEVE的财务顾问，Clifford Chance担任其法律顾问[3] Perrigo公司介绍 - Perrigo公司是一家领先的消费者自我护理产品提供商，致力于增强个人福祉，通过赋予消费者主动预防或治疗可自我管理的疾病来实现这一目标[4]

公司业绩 - Perrigo公司计划于2024年5月7日发布第一季度财务业绩[1] - 财报电话会议将通过网络直播和电话方式提供[2] 公司背景 - Perrigo公司是一家领先的消费者自我护理产品提供商[3] 风险和不确定因素 - 公司在未来展望声明中提到了一些风险和不确定因素[4]

Perrigo Has Opportunity to Leverage its Assets for More Profitable Future Paper Boat Creative/DigitalVision via Getty Images Perrigo (NYSE:PRGO) has increased dividends for 20 consecutive years, and I believe the initiatives outlined by the new CEO will propel Perrigo to Dividend Champion status and beyond. There are five potential catalysts forthcoming in 2024 that could support a share price increase. When combined with a depressed share price that is a result of a tumultuous decade, the shares seem to ha ...

Opill®产品介绍 - Opill®是美国首个无需处方即可购买的每日避孕药片，已经获得FDA批准，将在全国各大零售商和药店上架，并可在网上购买[1] - Opill®提供不同规格的包装，包括一个月和三个月的包装，建议零售价分别为$19.99和$49.99，此外还可在Opill.com购买三个月和六个月的供应，价格分别为$49.99和$89.99[3] - Opill®是一种口服避孕药，使用指导下的有效率达到98%，是目前美国唯一无需处方即可购买的最有效避孕方法，可帮助避免意外怀孕[4]

Perrigo公司活动 - Perrigo公司宣布总裁兼首席执行官Patrick Lockwood-Taylor和首席财务官Eduardo Bezerra将在3月13日下午4点在纽约市参加UBS全球消费者和零售业务会议[1] - 感兴趣的人可以在Perrigo网站上通过http://perrigo.investorroom.com/events-webcasts访问网络直播[2] Perrigo公司业务 - Perrigo公司是一家领先的消费者自我护理产品提供商，提供自我管理的OTC健康和健康解决方案，通过赋予消费者主动预防或治疗可自我管理的疾病来增强个人福祉[3] 前瞻性声明 - 该新闻稿包括Perrigo公司在UBS全球消费者和零售业务会议上讨论的一些“前瞻性声明”，涉及未来事件，涉及已知和未知的风险、不确定性和其他因素，其中许多超出公司的控制范围，可能导致公司的实际结果、绩效或成就与其当前的期望、假设、估计和投影大不相同[4]

Perrigo Company plc (PRGO) reported adjusted earnings of 86 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of 83 cents. Earnings were up 14.7% year over year. The upside can be attributed to lower operating expenses incurred by the company during the quarter.Net sales increased 0.1% year over year to $1.16 billion, missing the Zacks Consensus Estimate of $1.19 billion. The upside was driven by growth stemming from the acquisition of the U.S. & Canadian Good Start infant ...

财务数据和关键指标变化 - 2023财年净销售额增长近5%,主要得益于国际业务和美国OTC核心业务的表现 [12] - 2023财年毛利率扩大260个基点至38.8%,营业利润率扩大130个基点至12.3% [13] - 2023财年每股收益增长25%至2.58美元,现金流转换率达115% [13] 各条业务线数据和关键指标变化 - 2023财年各类别均实现增长,尤其是护肤、营养和女性健康类别,部分得益于收购HRA和Gateway [14] - 第四季度表现有所不同,健康生活方式和消化健康类别增长,感冒咳嗽类别在美国有中单位数增长,但在欧洲下降 [14][15] - 美国OTC自有品牌市场份额在最后13周增加70个基点,消费者继续青睐性价比产品 [15] 各个市场数据和关键指标变化 - 国际业务表现出色,美国OTC业务在消费环境正常化的情况下也表现良好 [9] - 第四季度美国OTC销售额高于消费,导致零售库存略有上升 [15] 公司战略和发展方向及行业竞争 - 公司正在推进"一个佩瑞高"的战略,简化和规模化业务,并推出"Project Energize"计划以提高效率和敏捷性 [25][35][36] - 公司计划通过推出Opill等品牌产品,建立以品牌为主的业务模式 [31][36][37] - 公司希望成为全球女性健康领域的领导者 [32] 管理层对经营环境和未来前景的评论 - 婴儿配方奶粉业务受到新监管要求的影响,公司正在采取行动加强和改善该业务 [19][20][21][22][23][24] - 2024年预计婴儿配方奶粉业务收益将低于2023年,但预计2025年可恢复到正常水平 [22][23] - 除婴儿配方奶粉外,公司其他业务在2024年有望实现中单位数的增长 [33][52] 问答环节重要的提问和回答 问题1 **Susan Anderson 提问** 询问婴儿配方奶粉业务的销售和利润恢复情况 [70][71] **Eduardo Bezerra 回答** 预计2024年上半年该业务仍低于去年,下半年开始恢复,2025年有望恢复到正常水平 [71][72] 问题2 **Chris Schott 提问** 询问公司是否有信心彻底解决婴儿配方奶粉业务的问题,以及对客户关系的影响 [84][87][89] **Patrick Lockwood-Taylor 回答** 公司采取了全面的改善措施,有信心解决问题,并与客户保持良好沟通 [85][86][87][88][89] 问题3 **Korinne Wolfmeyer 提问** 询问Opill产品的销售和供应情况 [96][97][98][99] **Patrick Lockwood-Taylor 和 Eduardo Bezerra 回答** Opill产品供应充足,第一年将有一定的投资,但对2024年整体影响有限 [97][98][99]

Perrigo (PRGO) reported $1.16 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.2%. EPS of $0.86 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.19 billion, representing a surprise of -2.51%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...